Advaxis Completes Pre-IND Meeting with FDA for Immunotherapy
At the meeting, the FDA addressed the Company's questions and provided guidance on the requirements to file an IND to initiate clinical trials.
Advaxis, Inc., a developer of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.
The FDA addressed the Company's questions and provided guidance on the requirements to file an IND to initiate clinical trials.
This IND is expected to be submitted in the first half of 2012.
"In our second pre-IND meeting of the year, the FDA continued to be collegial, receptive, and helpful as we take the necessary steps to expand our oncology pipeline,” said Dr. John Rothman, EVP of
Related News
-
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News CPHI Frankfurt 2022: Innovator Interviews – Bioiberica
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We caught up with Mónica Gómez Navarro (Marketing Manager Branded Ingredients), ... -
News CPHI Frankfurt 2022: Innovator Interview – Procaps Group
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We interviewed Rosella Del Vecchio Herrera, Marketing Director at Procaps Group, to discover h... -
News From the floor - CPHI Frankfurt 2022
The live blog from the people on the ground at CPHI Frankfurt - covering all stand-out news, memorable moments, and keynote updates from the 2022 event. -
News How to Commercialise an Advanced Therapy: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Andrea Zobel, Senior Director, Personalized Supply Chain at World Courier (Berlin Germany), Melissa Lattanzi, VP Emerging Therapies at AmerisourceBergen (King of Prussia, USA), and Hans-Peter Scherzer, Customer Suc... -
News CDMO - Health is a Joint Project: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Emanuele Agnese, Business Development Manager and Pietro Allegrini, R&D Director at Indena, present the ways in which a reliable manufacturing partner in the pursuit of better health outcomes for patients and pharm... -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv... -
News MDR – How to collect post-market clinical follow-up data (PMCF): Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Philipp Annecke, Junior Key Account Manager and Heinrich Martens, VP Regulatory Affairs of Fresenius Kabi (Bad Homburg, Germany) present guidances from the Medical Devices Regulation on clinical data evaluatio...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance